Waverley Pharma Announces Resignation of CEO and Appointment of New CEO

About this update from Waverley Pharma, Inc.

[{"type":"text","content":"\n\n\n\nWaverley Pharma Announces Resignation of CEO and Appointment of New CEO\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, July 23, 2018\n\n\n\nPharmaceutical Veteran Dr. Theron (Ted) Odlaug Assumes CEO role upon the Resignation of Dr. George Thomas\n\n\n\nWINNIPEG, July 23, 2018 /CNW/ - Waverley Pharma Inc. (\"Waverley Pharma\" or the \"Company\") (TSXV: WAVE), an emerging Canadian pharmaceutical company, announced today that its board of directors (the \"Board\") has accepted the resignation of Dr. George Thomas as President and Chief Executive Officer (CEO) of the Company, effective July 26, 2018, as he has decided to pursue other opportunities.\n\nDr. Theron (Ted) Odlaug has been appointed by the Board as the new CEO, effective August 1, 2018.  Dr. Odlaug is currently the Executive Chairman of Impopharma Inc. and most recently was the CEO of leon-nanodrugs GmbH, based in Munich, Germany. Prior to that he was the Executive Chairman of Cedarburg Pharmaceuticals, and has over 35 years business experience that includes senior leadership roles at Astellas, Fujisawa, Bayer AG and Baxter.\n\nDr. Albert Friesen, Chairman of Waverley Pharma said, \"The Board is very thankful to George for his exemplary service to the Company and wishes him much success in his future endeavors. On behalf of the Board I would also like to welcome Ted to the team and we look forward to working with him as he brings his extensive experience and knowledge to the Company.\"\n\nWaverley Pharma also announced today that it has authorized the grant of an aggregate of 400,000 stock options (each an \"Option\") to certain directors and officers of the Company and its subsidiaries in accordance with the Company's stock option plan. Each Option will be exercisable into one common share of the Company at the closing market price of the Company's common shares on the date of grant, for a period of five years from the date of grant. The issuance of the Options is subject to the approval of the TSX Venture Exchange.\n\nAbout Wav...

More updates from Waverley Pharma, Inc.